• Login
    View Item 
    •   Home
    • Graduate Theses, Dissertations and Projects
    • Queen's Graduate Theses and Dissertations
    • View Item
    •   Home
    • Graduate Theses, Dissertations and Projects
    • Queen's Graduate Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Assessment of a Novel Phosphate Binding Therapy in Experimental Adenine-Induced Chronic Kidney Disease

    Thumbnail
    View/Open
    Jeronimo_Paul_S_201708_MSC.pdf (2.152Mb)
    Author
    Jeronimo, Paul
    Metadata
    Show full item record
    Abstract
    Hyperphosphatemia is a hallmark of progression in chronic kidney disease (CKD) and has been linked to the development of vascular calcification (VC), which increases cardiovascular risk. Phosphate binders are prescribed to control hyperphosphatemia. Fermagate is a calcium-free, magnesium-releasing, phosphate binder. Oral delivery of magnesium has been shown to attenuate VC. The aim of this study was to determine whether fermagate treatment compared to no treatment could impact VC in male Sprague-Dawley rats using an experimental model of adenine-induced CKD. The effect of fermagate on two different high phosphate dietary regimens was performed: high phosphate (0.75%) diet at all meals or a combination of low (0.5%) and high (1%) phosphate meals, such that the total amount of phosphate delivered was the same. In both studies, administration of fermagate increased serum magnesium and attenuated the levels of circulating phosphate, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23). Compared to untreated CKD rats, fermagate treatment significantly reduced the prevalence of VC across a range of vascular tissues (70% VC in treated vs. 24% VC in untreated), but did not alter the accrual of magnesium in the vasculature. Serum phosphate and the prevalence of VC were higher in untreated and fermagate-treated rats on the constant high (0.75%) diet compared to the combination diet (0.5/1%), suggesting the impact of phosphate is dependent on the delivery of phosphate, not only the amount of phosphate consumed. Overall, the findings demonstrate that fermagate effectively reduces the bioavailability of the dietary phosphate load, increases systemic levels of magnesium, and limits the development and progression of CKD and VC.
    URI for this record
    http://hdl.handle.net/1974/22037
    Collections
    • Department of Biomedical and Molecular Sciences Graduate Theses
    • Queen's Graduate Theses and Dissertations
    Request an alternative format
    If you require this document in an alternate, accessible format, please contact the Queen's Adaptive Technology Centre

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us
    Theme by 
    Atmire NV
     

     

    Browse

    All of QSpaceCommunities & CollectionsPublished DatesAuthorsTitlesSubjectsTypesThis CollectionPublished DatesAuthorsTitlesSubjectsTypes

    My Account

    LoginRegister

    Statistics

    View Usage StatisticsView Google Analytics Statistics

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us
    Theme by 
    Atmire NV